<!doctype html>
<html lang="en">
<head>

<title>Screen</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8">
    <link rel="stylesheet" type="text/css" href="css/page12.css" />
	<script>
	$(document).ready(function(){
        $('#audio-slideshow').udSynch();
	     
		    $(".nextFrame").text("Click/Tap forward arrow to continue");
            $(".disable_block").hide();
        $(".timeline-disable").hide();
                 $(".audio-play_1").removeClass("disable-play-icon");
        $(".audio-pause").removeClass("disable-pause-icon");
        $(".replay-audio").removeClass("disable-replay-icon");
        $(".jp-mute").removeClass("disable-mute-icon");
          $(".nextFrame").removeClass("hide");
		  
	});
	</script>
<style type="text/css">
    .popup_frame8{    float: none;
    position: relative;
    z-index: 80;
    width: 70%;
    background: #fff;
    margin: -95px auto;
    height: 328px;
    border-radius: 10px;
    border: 2px solid #f4f4f4;}
    .popup_overlay8{    float: none;
    position: relative;
    z-index: 70;
    width: 1024px;
    background-color: rgba(0, 0, 0, 0.6);
    margin: -413px auto;
    height: 531px;
    /* border-radius: 10px; */
    /* border: 2px solid #f4f4f4; */
    opacity: 0.5;
        -webkit-opacity:0.5;

-moz-opacity:0.5;

    right: 24px;}
    </style>
    </head> 
    <body> 
	  <div class="row">
        <div class="col s12">
            <div class="audio-slides">
                <div class="animated fadeIn" data-slide-time="0">
                <div class="image-box">
                     <img src="images/f12/left-image.png" />
                    </div>
                </div>
                <div class="page_box2  animated fadeInDown" data-slide-time="0.5">
                 <div class="box-title">Small Bowel Obstruction</div>
                   <div class="col s12 learning-objective">
        
                   </div>
              </div>
          <div class="bullet-background-image animated fadeInRight bullet1" data-slide-time="1">It is the blockage of the small intestine</div>
          <div class="bullet-background-image animated fadeInRight bullet2" data-slide-time="5">Adhesions may be the cause of 65% to 75% of SBO</div>
          <div class="bullet-background-image animated fadeInRight bullet3" data-slide-time="9">SBO event caused by an adhesion is referred to as ASBO</div>
                    <div class="bullet-background-image animated fadeInRight bullet4" data-slide-time="10">Adhesions that extend between the bowel and the adjacent structures may restrict</div>
                  <div class="subbullet-background-image animated fadeInRight bullet5" data-slide-time="12">Mobility</div>
				<div class="subbullet-background-image animated fadeInRight bullet6" data-slide-time="14">Natural flow of bowel contents</div>
				
				                    <div class="audio-slides">
                     <div class="bullet-background-image animated fadeInRight bullet1" data-slide-time="16">Incidence of intraperitoneal postsurgical adhesions following pelvic surgery in women has been reported to be between 55% and 100%</div>  
           <div class="bullet-background-image animated fadeInRight bullet2" data-slide-time="18">Most common site of adhesion formation is the ovaries</div>
 <div class="bullet-background-image animated fadeInRight bullet2" data-slide-time="20">About 20% of the patients are readmitted within 1 year for an additional open gynecologic procedure complicated by adhesions
</div>         
<div class="bullet-background-image animated fadeInRight bullet2" data-slide-time="22">Presence and severity of adhesions increase with each subsequent cesarean delivery
</div>
<div class="bullet-background-image animated fadeInRight bullet2" data-slide-time="24">The efficacy and safety of Seprafilm®, in relation to reduction of adhesion in cesarean section, has not been confirmed in well-controlled clinical trials
                        </div>
            </div>
				
			  
                <div class="popup_frame8 animated fadeIn poptext" data-slide-time="26">When interacting with Health Care Professionals, you must discuss all three points related to SBO reduction included in the Clinical Studies Section of Seprafilm’s FDA-approved labeling. Specifically, in a post-approval study of Seprafilm<sup>®</sup> of 1791 patients undergoing adhesiolysis for existing SBO:
				<ul>
				<li class="popbullet1 bullet-background-image" style="list-style-type:none;" data-slide-time="28">Using protocol defined criteria, 15 of the 840 intestinal resection patients (1.8%) in the Seprafilm<sup>®</sup> group experienced an adhesive SBO that required reoperation compared to 29 of 861 intestinal resection patients (3.4%) in the control group (p<0.05).</li>
				<li class="popbullet1 bullet-background-image" style="list-style-type:none;" data-slide-time="30">When all cases of bowel obstruction were considered, including those in which bowel obstruction could not be ruled out, 109 of 888 patients (12%) in the Seprafilm<sup>®</sup> group and 106 of 903 patients (12%) in the control group had bowel obstruction.</li>
				<li class="popbullet1 bullet-background-image" style="list-style-type:none;" data-slide-time="32">Of the 90 patients with existing bowel obstructions, no significant difference in incidence of adhesive SBO requiring reoperation was found (3 of the 48 Seprafilm<sup>®</sup> patients versus 1 of 42 control patients).</li>
				</ul>            
			</div>
                           <div class="popup_overlay8 animated fadeIn" data-slide-time="34"></div>
		</div>

          
        </div>
        </div>
</body>
</html>


